← All companies
Novo Nordisk A/S

Novo Nordisk A/S

NVO · NYSE · Pharmaceuticals

Novo Nordisk A/S is one of the world’s leading pharmaceutical companies, focused on treating serious chronic diseases.

Current price

$38.08

▲ +$0.02 (0.05%) today

Share price

Live market data
▼ -19.42 (-33.77%)2025-10-13 — 2026-10-14
$65.70$59.27$52.85$46.42$40.00$33.572025-10-132026-10-14
Add to my portfolio Add to watchlistCompare →

ET&A View

Last reviewed 16 September 2026

Buy

ET&A sees significant upside from the current price with an attractive risk/reward profile.

Fair Value
Members
12M Price Target
Members
Preferred Entry
Members
ET&A Score
8.4/ 10Strong overall
Members see what we think Novo Nordisk A/S is worth today, our 12-month Price Target, the price we would prefer to buy at and the return we expect. See membership

Novo Nordisk remains one of the world's highest-quality pharmaceutical franchises, supported by dominant positions in diabetes and obesity, exceptional profitability and a globally recognised GLP-1 portfolio.

Is it expensive?

Read our full view

Why we like it

  • Profits are growing fast (+1%).
  • Very profitable — keeps about 43% of its sales as profit.
  • Sales are growing quickly (+6% a year).

What worries us

  • The share price has been weak recently.
  • The share price swings more than most.
Members see every risk we are watching. See membership

Business Health

Is the business financially healthy?

Yes — very healthy

Revenue, earnings, margins, cash generation and the balance sheet stand out.

Overall

Excellent

  • Revenue

    DKK 329.4bn · ↑ +6% last year

    Growth Excellent

  • Earnings

    DKK 116.4bn · ↑ +1% last year

    Growth Excellent

  • Margins

    Keeps 43% of sales as operating profit

    Excellent

  • Cash generation

    DKK 29.0bn spare cash a year · 9% of sales

    Strong

  • Balance sheet

    Debt ≈ 0.5 years of earnings

    Strong

  • Dividend

    4.7% yield · Pays out 45% of earnings · covered 2.2×

    Yield Strong
Financial and earnings trends

Investor View

More on Novo Nordisk A/S

Open a section for the detail behind the quick view.

Our full viewET&A's complete thesis — why we hold the view we do.

Novo Nordisk remains one of the world's highest-quality pharmaceutical franchises, supported by dominant positions in diabetes and obesity, exceptional profitability and a globally recognised GLP-1 portfolio. The…

Insight

The complete ET&A view

See our full reasoning, what could drive the shares higher or go wrong, our Fair Value and Preferred Entry, and how our view has changed.

  • Our View in full
  • What could drive it higher / go wrong
  • Fair Value & Preferred Entry
  • How our view has changed
Explore Insight →Included with Insight
What could drive it higher — and what could go wrongThe catalysts and risks we are watching.
Members see every catalyst and risk we are watching. See membership
Valuation discussionWhere today's price sits, and how it compares with the company's own history and its peers.
Members see where the price sits against our valuation, its history and its peers. See membership
Who it suitsStrategy suitability and investment style.

Long-term investors who want growth and income

Also suits: Investors who want a mix of growth and stability

Investment styleQualityGrowthValueET&A strategies: Income, Balanced, Growth · what these mean
How it compares with peersOther companies we cover in Pharmaceuticals.
  • AstraZeneca plcAZN

    ET&A sees significant upside from the current price with an attractive risk/reward profile.

    BuyET&A Score 8.7Compare →
  • Eli Lilly and CoLLY

    ET&A sees significant upside from the current price with an attractive risk/reward profile.

    BuyET&A Score 8.5Compare →
  • Merck & Co. IncMRK

    ET&A likes the company but would prefer investors to build exposure gradually.

    AccumulateET&A Score 8.4Compare →
  • Novartis AGNOVN

    ET&A likes the company but would prefer investors to build exposure gradually.

    AccumulateET&A Score 8.4Compare →

Compare Novo Nordisk A/S with any company → The model’s own peer calculations are in the Research View.

What the company doesThe full company profile.

Novo Nordisk A/S is one of the world’s leading pharmaceutical companies, focused on treating serious chronic diseases. The company is best known for its leadership in diabetes and obesity care, with major products across insulin, GLP-1 therapies, weight management, and related metabolic conditions. It also has important positions in rare blood disorders, rare endocrine disorders, and other specialist treatment areas.

Novo Nordisk’s strength comes from its deep scientific expertise, global manufacturing scale, trusted healthcare brand, and dominant position in some of the fastest-growing areas of pharmaceutical demand. Its diabetes and obesity franchises give it exposure to major long-term health challenges, while its wider pipeline and rare disease portfolio provide additional growth opportunities. As demand rises for treatments targeting obesity, diabetes, cardiovascular risk, and related chronic conditions, Novo Nordisk remains one of the most important companies in global healthcare.

Pharmaceuticals · Denmark

Research ViewOpen the full researchFull financial statements, valuation multiples, historical data, forecasts, methodology, scoring calculations and the valuation model.

For detailed analysis. Each section opens on its own.

Financial statementsEvery published figure with its source, the market snapshot and connected sheets.

Income

Revenue
DKK 329.4bn
Gross profit
DKK 270.1bn
EBITDA
DKK 173.7bn
Operating profit (EBIT)
DKK 127.7bn
Net income
DKK 116.4bn
Earnings per share (EPS)
DKK 4.09

Growth

Revenue growth, latest year
6.4%
Revenue growth, 3-year average
20.4%
Earnings growth, latest year
1.4%
Earnings growth, 3-year average
22.6%
Revenue growth, latest quarter vs a year earlier
2.1%
Earnings growth, latest quarter vs a year earlier
−20.6%

Margins & returns

Gross margin
82.0%
EBITDA margin
52.7%
Operating margin
42.5%
Net margin
35.3%
Return on equity (ROE)
59.8%
Return on assets (ROA)
18.7%

Cash flow

Operating cash flow
DKK 131.9bn
Free cash flow
DKK 29.0bn
Free-cash-flow margin
8.8%
Free cash flow ÷ net income
0.2×

Balance sheet

Cash
DKK 45.0bn
Total debt
DKK 140.1bn
Net debt
DKK 95.1bn
Net debt ÷ EBITDA
0.5×
Debt ÷ equity
0.6×
Current ratio
0.9×

Shares & dividends

Shares outstanding
3.34bn
Market capitalisation
DKK 168.2bn
Dividend per share
DKK 11.70
Dividend yield
4.7%
Payout ratio
45.1%
  • Market data — the live feed (Yahoo Finance)
  • Calculated — worked out by ET&A from the figures shown, using the formulas in our methodology

Other published figures

Price / Sales
Members
EV / EBITDA
Members
Price / Book
Members
Forward P/E
Members
Valuation ratios (P/E, P/S, P/B, EV/EBITDA) are part of ET&A membership — view plans.

Market data

Live
Price$38.08
Day+$0.02 (+0.05%)
52-week range$35.29 – $63.98
vs 52-week low+7.91%
vs 52-week high−40.48%

As of 14 October 2026

P/E Ratio
9.32x
Valuation multiplesP/E, forward P/E, EV/EBITDA, Price/Sales and FCF yield — today and at Fair Value.

Standard ways of comparing the share price with the company’s earnings, sales and cash. Tap the “i” for what each one means.

MeasureTodaySource
P/EMembers
Forward P/EMembers
EV/EBITDAMembers
Price/SalesMembers
FCF YieldMembers

Valuation ratios are part of ET&A membership.

Other published measures

Price / Book
Members
Historical dataValuation history, how our view has changed, and the share-price history.

Valuation history

Members see how the valuation compares with its history. See membership

Share-price history

Use the 5Y and Max ranges on the price chart at the top of the page.

ForecastsWhat analysts expect — market consensus, not ET&A estimates.

Forecasts

Forward EPS (next year, consensus)
DKK 3.31
Expected EPS growth, next year
−2.8%
Expected revenue growth, next year
−2.6%

Forecasts are market consensus or calculated from forward EPS — not ET&A estimates, and they can be wrong.

MethodologyHow ET&A values a company and reaches a view.

How we value Novo Nordisk A/S

  1. 1. The right method for the business. Each business is valued on the method that suits its economics — earnings for most companies, book value and returns for banks and insurers, cash flows or dividends where earnings mislead.
  2. 2. What the business deserves. ET&A builds a fair multiple from the company's own quality, sustainable growth, earnings predictability and risk. History, peers and the market are checked against it, but they don't set it.
  3. 3. Fair Value. The earnings (or other basis) per share multiplied by that fair multiple, cross-checked against independent methods.
  4. 4. Preferred Entry. A price below Fair Value that leaves room for the return ET&A requires for the company's risk.
  5. 5. Is it expensive? Today’s price is placed on ET&A’s Valuation Attractiveness scale — the same measure the ET&A Score uses. Cheap is the Preferred Entry; above Fair Value the shares are Expensive, and Very Expensive once they are more than 25% above it.

Powered by the ET&A Valuation FrameworkHow Fair Value & Preferred Entry work →

Read the full ET&A methodology →

How we reach a view

The ET&A View combines our assessment of the business with where today’s price sits against our Preferred Entry and Fair Value. It is a considered judgement, not a mechanical score.

  • Business quality
  • Financial performance
  • Growth outlook
  • Debt and financial strength
  • Valuation
  • Risk
  • What could drive it higher
Buy
ET&A sees significant upside from the current price with an attractive risk/reward profile.
Accumulate
ET&A likes the company but would prefer investors to build exposure gradually.
Hold
ET&A sees limited reason to buy aggressively or sell at the current price.
Reduce
ET&A believes the current valuation or risk profile makes a smaller position more appropriate.
Sell
ET&A believes the downside risk materially outweighs the potential return at the current price.

ET&A Score: ET&A's overall assessment of business quality, valuation, growth and risk, out of 10. It weighs business quality, financial strength, growth, valuation, risk, future prospects.

Powered by the ET&A Company Assessment FrameworkSee the full framework →

Scoring calculationsBehind the ET&A Score and the Business Health ratings.

Behind the ET&A Score

The automatic, rules-based scores that feed our research. The ET&A Score blends these with our own analysis of the business and its value. How the framework works →

ET&A Quant Score

7.1/ 10Favourable

Highly profitable · Strong balance sheet · Weak

Profitability & margins · Highly profitable10.0
Balance sheet · Strong balance sheet7.7
Price momentum · Weak0.4

Context — not part of the score

  • Valuation multiplesInexpensive
  • Share-price steadinessVery high volatility
  • IncomeModerate yield

Valuation and share-price swings describe the shares, not the company, so they are judged in the ET&A Score and View instead.

Annualised volatility
Members
Max drawdown (1y)
Members
12-month return
Members
3-month return
Members
P/E
Members
Price / Sales
Members
EV / EBITDA
Members
EBITDA margin
Members
Net debt / EBITDA
Members
Dividend yield
Members
The detailed figures behind these scores — price swings, past falls, returns, valuation and margins — are part of ET&A membership. View plans

Based on the factors that could be measured (45% of the model).

Business Health ratings

Each area is scored from 0 to 10 on ET&A’s methodology scales — the same ones our research uses — then given a word: Excellent from 8.5, Strong from 7, Good from 5.5, Average from 4.5, Below Average from 3, Weak below 3. The overall answer is the average of the areas we could rate (at least three); the dividend isn’t part of it.

AreaBased onScoreRating
Revenue
  • Revenue growth, 3-year average 20.4% → 9.0

Rated on 3-year average revenue growth, on ET&A's growth scale.

9.0 / 10Excellent
Earnings
  • Earnings growth, 3-year average 22.6% → 9.3

Rated on 3-year average earnings growth, on ET&A's growth scale.

9.3 / 10Excellent
Margins
  • Operating margin 42.5% → 9.5
  • Net margin 35.3% → 9.0

The average of operating and net margin, each scored on ET&A's margin scales. A negative margin scores 1 (Weak).

9.3 / 10Excellent
Cash generation
  • Free-cash-flow margin 8.8% → 7.1

Free cash flow as a share of sales, on ET&A's cash-generation scale.

7.1 / 10Strong
Balance sheet
  • Net debt ÷ EBITDA 0.5× → 8.0

Net debt ÷ EBITDA — roughly how many years of operating earnings would repay the debt — on ET&A's leverage scale.

8.0 / 10Strong
Dividend
  • Dividend yield 4.7% → 7.7

Dividend yield on ET&A's income scale. Not part of the overall health rating.

7.7 / 10Strong
OverallAverage of the 5 rated areas8.5 / 10Excellent

ET&A's scales

Where each band starts on the scales above. They are fixed and identical for every company we cover; they come straight from ET&A’s methodology, so a company is judged the same way here as in our research.

MeasureExcellentStrongGoodAverageBelow AverageWeak
GrowthStructural Growth (Fundamental Conviction)18%+10%+5.0%+1.7%+−2.5%+below −2.5%
Operating marginCompetitive Position (Fundamental Conviction)29%+20%+13%+7.5%+0%+below 0% (loss)
Net marginEarnings Durability (Fundamental Conviction)23%+15%+9.8%+6.0%+0%+below 0% (loss)
Free-cash-flow marginCapital Allocation (Fundamental Conviction)15%+8.5%+3.8%+1.3%+−2.5%+below −2.5%
Net debt ÷ EBITDAStructural Risk (Fundamental Conviction)net cash≤ 1.5×≤ 2.8×≤ 3.6×≤ 5.0×above 5.0×
Return on equity (banks & insurers)Bank and insurer quality16%+12%+9.0%+6.7%+2.7%+below 2.7%
Equity ÷ assetsBank capital7.5%+6.0%+4.7%+4.0%+any—
Dividend yieldIncome factor (ET&A Quant Score)5.8%+4.0%+2.5%+1.8%+1.0%+below 1.0%

Band floors: Excellent 8.5 · Strong 7 · Good 5.5 · Average 4.5 · Below Average 3 (scores out of 10). Utilities and property companies’ structural debt is scored 6.5, as in ET&A’s risk model.

Valuation model outputsFair Value, the 12-Month Price Target, Preferred Entry and the expected return — and how each was calculated.
Members see how we calculate the Fair Value and Preferred Entry. See membership
Peer calculationsThe comparable companies the valuation model used, with their multiples and returns.
Members see the peer set behind our valuation. See membership
Detailed assumptionsEvery input the valuation model used, with its source.
Members see the assumptions behind our valuation. See membership
Research notesNo research notes published yet.

No research notes have been published for Novo Nordisk A/S yet.

Need deeper analysis on Novo Nordisk A/S? ET&A Professional includes full company notes, valuations and models — or commission bespoke research.

Explore Professional →Commission research

Read more

All insights →
Electricity Is Becoming the World's Most Important Industrial Advantage
INSIGHTTechnology & InfrastructureInsight

Electricity Is Becoming the World's Most Important Industrial Advantage

The last era of globalisation was shaped by cheap labour. The next could be shaped by cheap electrons. As AI, semiconductors, electric vehicles and advanced manufacturing consume extraordinary amounts of power, the countries able to provide abundant, reliable and inexpensive electricity may acquire one of the most important economic advantages of the next decade.

A. Francis Ugbabe · 29 September 2026 · 14 min read

The Rate-Cutting Cycle May Be Over Before It Really Began
INSIGHTMarkets and EconomicsInsight

The Rate-Cutting Cycle May Be Over Before It Really Began

The Federal Reserve is increasingly expected to raise interest rates this week. The more important question for investors is whether this represents a one-off response to inflation—or the beginning of an entirely new market regime.

ET&A Research · 14 September 2026 · 8 min read

Lululemon Shows Why Premium Brands Cannot Rely on Pricing Power Forever
INSIGHTCompaniesInsight

Lululemon Shows Why Premium Brands Cannot Rely on Pricing Power Forever

Lululemon spent years proving that consumers would pay premium prices for athletic clothing. Its recent struggles show the other side of pricing power: a premium can disappear remarkably quickly when product differentiation and cultural relevance begin to fade.

ET&A Research · 7 September 2026 · 9 min read